{
    "clinical_study": {
        "@rank": "168157", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Subjects with normal renal function", 
                "arm_group_type": "Experimental", 
                "description": "Asunaprevir 100 mg tablet by mouth twice daily for 7 days"
            }, 
            {
                "arm_group_label": "Arm B: Subjects with end stage renal disease", 
                "arm_group_type": "Experimental", 
                "description": "Asunaprevir 100 mg tablet by mouth twice daily for 7 days"
            }, 
            {
                "arm_group_label": "Arm C: Subjects with mild renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "Asunaprevir 100 mg tablet by mouth twice daily for 7 days"
            }, 
            {
                "arm_group_label": "Arm D: Subjects with moderate renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "Asunaprevir 100 mg tablet by mouth twice daily for 7 days"
            }, 
            {
                "arm_group_label": "Arm E: Subjects with severe renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "Asunaprevir 100 mg tablet by mouth twice daily for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine how Asunaprevir is handled by the body of subjects\n      with kidney disease compared with subjects with normal kidney function"
        }, 
        "brief_title": "Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Purpose:\n\n      Other: The purpose of the study is to determine how Asunaprevir is handled by the body of\n      subjects with kidney disease compared with subjects with normal kidney function"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Group A: Subjects with normal renal function\n\n          -  Group B: Patients with end stage renal disease\n\n          -  Group C: Patients with mild renal impairment\n\n          -  Group D: Patients with moderate renal impairment\n\n          -  Group E: Patients with severe renal impairment\n\n        Exclusion Criteria:\n\n          -  History of uncontrolled or unstable cardiovascular, respiratory, hepatic,\n             gastrointestinal, endocrine, hematopoietic, psychiatric and/or neurological disease\n\n          -  Hepatitis B or C\n\n          -  Human Immunodeficiency Virus (HIV)\n\n          -  Recent gastrointestinal disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886599", 
            "org_study_id": "AI447-033"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A: Subjects with normal renal function", 
                "Arm B: Subjects with end stage renal disease", 
                "Arm C: Subjects with mild renal impairment", 
                "Arm D: Subjects with moderate renal impairment", 
                "Arm E: Subjects with severe renal impairment"
            ], 
            "intervention_name": "Asunaprevir", 
            "intervention_type": "Drug", 
            "other_name": "BMS-650032"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Davita Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "New Orleans Center For Clinical Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Open-Label, Parallel Group, Multiple-Dose Study to Evaluate the Pharmacokinetics and Safety of Asunaprevir in Subjects With Renal Function Impairment", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Area under the concentration-time curve in one dosing interval [AUC(TAU)] will be calculated from the blood drug concentration versus time curve", 
            "measure": "AUC(TAU) of Asunaprevir assessed using plasma concentrations on Day 7", 
            "safety_issue": "No", 
            "time_frame": "11 time points on Day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886599"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma protein binding (PB) of Asunaprevir will be determined from the 1 hour and 3 hour time points post-dose", 
                "safety_issue": "No", 
                "time_frame": "1 and 3 hours of Day 7"
            }, 
            {
                "description": "Pharmacokinetic (PK) parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Maximum observed plasma concentration (Cmax) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Unbound Maximum observed plasma concentrations (Cmaxu) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Time of maximum observed plasma concentration (Tmax) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Minimum observed plasma concentration at one dose interval (C12) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Minimum observed plasma concentration at Pre-AM dose (Ctrough) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "3 time points up to Day 7 (blood) and 2 time points on Days 1 and 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Unbound area under the concentration-time curve in one dosing interval [AUC(TAU)u] of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Area under the concentration-time curve till time of last sampling [AUC(0-T)] of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "11 (blood) and 2 (urine) time points on Day 7"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Terminal elimination half life (T-Half) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Percent urinary recovery (%UR) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Apparent total body clearance (CLT/F) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Unbound apparent clearance (CLU/F) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Renal clearance (CLR) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Apparent volume of distribution (Vd/F) of Asunaprevir", 
                "safety_issue": "No", 
                "time_frame": "30 time points up to Day 10 (blood) and 3 time points up to Day 7 (urine)"
            }, 
            {
                "description": "PK parameters will be derived from plasma concentration versus time and urinary excretion data (not applicable for subjects who are anuric)", 
                "measure": "Accumulation index (AI): Ratio of AUC(TAU) on Day 7 to AUC(TAU) on Day 1", 
                "safety_issue": "No", 
                "time_frame": "22 (blood) and 3 (urine) time points on Days 1 and 7"
            }, 
            {
                "description": "All recorded adverse events (AEs) will be listed and tabulated by system organ class, preferred term and renal function group. Vital signs and clinical laboratory test results will be listed and summarized by renal function group and time. Any significant physical examination findings and clinical laboratory results will be listed. Electrocardiogram (ECG) readings will be evaluated by the investigator and abnormalities, if present, will be listed", 
                "measure": "Safety and tolerability endpoints include all AEs and serious AEs, clinical laboratory tests, ECGs, vital signs and physical examination results", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 15 and until 30 days post discontinuation of dosing"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}